Literature DB >> 7851607

Massive deep vein thrombosis in a patient with antithrombin III deficiency undergoing ovarian stimulation for in vitro fertilization.

I Kligman1, N Noyes, C A Benadiva, Z Rosenwaks.   

Abstract

OBJECTIVE: To present the first report of a thromboembolic complication in early pregnancy after ovarian hyperstimulation for IVF in a patient with AT III deficiency who was treated successfully and subsequently delivered a healthy male infant at 32 weeks of gestation.
DESIGN: Case report.
SETTING: Hospital-based clinic for reproductive medicine. PATIENT: A 28-year-old woman who consulted our IVF clinic with a 3.5-year history of primary infertility.
INTERVENTIONS: Intravenous heparin therapy.
RESULTS: The patient responded adequately to heparin therapy and was discharged home on SC heparin. A primary cesarean section was performed at 32 weeks of gestation because of poor fetal growth and transverse lie.
CONCLUSIONS: We stress the importance of obtaining a thorough personal and family history before initiation of ovarian hyperstimulation. Measuring activity of AT III, protein C, and protein S in patients with a suspicious history of thromboembolic episodes occurring at an early age may lead to the implementation of appropriate prophylactic measures, preventing potentially life-threatening complications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7851607     DOI: 10.1016/s0015-0282(16)57446-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Thrombophilia and ovarian hyperstimulation syndrome: a case report.

Authors:  Gary Levy; Richard S Lucidi
Journal:  Hawaii Med J       Date:  2011-05

2.  Treatment outcomes and quality-of-life assessment in a university-based fertility preservation program: results of a registry of female cancer patients at 2 years.

Authors:  Andrea E Reh; Lucy Lu; Rachel Weinerman; James Grifo; Lewis Krey; Nicole Noyes
Journal:  J Assist Reprod Genet       Date:  2011-03-22       Impact factor: 3.412

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.